<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) following bone marrow transplant is an important cause of morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Oral involvement in <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD occurs frequently and occasionally is the manifestation of greatest concern to the patient </plain></SENT>
<SENT sid="2" pm="."><plain>Management with systemic immunosuppression is the principal approach to therapy although topical application of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> may also be beneficial </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated the use of cyclosporin administered as an oral rinse in patients with oral GVHD which remained active despite the prior use of systemic immunosuppression plus topical <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Signs and symptoms of ulcerative oral GVHD improved &gt; or = 50% in 7 of 11 patients (64%) treated with the addition of topical <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The topical use of <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> may represent a useful adjunctive approach in the management of oral GVHD </plain></SENT>
</text></document>